Altium Capital Management LP acquired a new stake in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 228,714 shares of the biopharmaceutical company’s stock, valued at approximately $1,578,000. Altium Capital Management LP owned about 0.45% of Marinus […]
StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report issued on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Other equities research analysts have also issued research reports about the company. Robert W. Baird dropped their price objective on Marinus Pharmaceuticals from $24.00 to […]
Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) had its price target lowered by Truist Financial from $42.00 to $32.00 in a research report released on Friday morning, Marketbeat reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. Several other brokerages also recently weighed in on MRNS. Oppenheimer downgraded shares of Marinus Pharmaceuticals […]
Tekla Capital Management LLC acquired a new position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 456,780 shares of the biopharmaceutical company’s stock, valued at approximately $3,152,000. Tekla Capital Management LLC owned approximately […]
Marinus Pharmaceuticals (NASDAQ:MRNS – Get Free Report) was downgraded by equities research analysts at Oppenheimer from an “outperform” rating to a “market perform” rating in a research note issued to investors on Friday, MarketBeat reports. They presently have a $9.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $14.00. […]